Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib with or without apatinib versus placebo as maintenance therapy after first-line platinum chemotherapy for advanced ovarian cancer
CTR20200217Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of fluzoparib, Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hengrui Therapeutics. Started Jun 2020; status: active.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20200217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200217.